United Therapeutics (NASDAQ:UTHR) Director Jan Malcolm Sells 50 Shares

United Therapeutics Corporation (NASDAQ:UTHR) Director Jan Malcolm sold 50 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $495.01, for a total transaction of $24,750.50. Following the completion of the sale, the director directly owned 370 shares in the company, valued at $183,153.70. This represents a 11.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Jan Malcolm also recently made the following trade(s):

• On Tuesday, December 23rd, Jan Malcolm sold 50 shares of United Therapeutics stock. The shares were sold at an average price of $512.12, for a total transaction of $25,606.00.
• On Thursday, December 11th, Jan Malcolm sold 50 shares of United Therapeutics stock. The stock was sold at an average price of $482.98, for a total transaction of $24,149.00.

United Therapeutics Trading Up 2.7%

UTHR traded up $13.02 during midday trading on Tuesday, reaching $502.71. The company’s stock had a trading volume of 306,680 shares, compared to its average volume of 483,021. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $519.99. The stock’s 50-day moving average is $479.72 and its 200-day moving average is $397.27. The firm has a market capitalization of $21.65 billion, a price-to-earnings ratio of 19.05, a PEG ratio of 4.77 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.89 by $0.27. The firm had revenue of $799.50 million during the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business’s revenue was up 6.8% on a year-over-year basis. During the same period last year, the business earned $6.39 earnings per share. As a group, equities research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. CWM LLC raised its stake in United Therapeutics by 204.3% during the second quarter. CWM LLC now owns 5,194 shares of the biotechnology company’s stock valued at $1,492,000 after purchasing an additional 3,487 shares in the last quarter. AXQ Capital LP grew its stake in shares of United Therapeutics by 495.4% in the 2nd quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock worth $1,117,000 after buying an additional 3,235 shares in the last quarter. Osaic Holdings Inc. increased its holdings in shares of United Therapeutics by 271.0% in the 2nd quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company’s stock worth $14,027,000 after buying an additional 33,662 shares during the last quarter. Simplify Asset Management Inc. bought a new stake in shares of United Therapeutics in the 3rd quarter worth about $8,351,000. Finally, Wealth Enhancement Advisory Services LLC raised its position in shares of United Therapeutics by 77.4% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 6,084 shares of the biotechnology company’s stock valued at $1,792,000 after buying an additional 2,655 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

UTHR has been the subject of several analyst reports. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. Royal Bank Of Canada lifted their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a report on Thursday, October 30th. Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a research note on Wednesday, October 29th. Finally, UBS Group increased their price target on shares of United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a report on Tuesday. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $509.50.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.